Pharmacogenetic Analysis in Mice

Information

  • Research Project
  • 6889604
  • ApplicationId
    6889604
  • Core Project Number
    R01GM068885
  • Full Project Number
    5R01GM068885-02
  • Serial Number
    68885
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2004 - 20 years ago
  • Project End Date
    4/30/2007 - 17 years ago
  • Program Officer Name
    RAPAKA, RAO
  • Budget Start Date
    5/1/2005 - 19 years ago
  • Budget End Date
    4/30/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    2
  • Suffix
  • Award Notice Date
    4/28/2005 - 19 years ago
Organizations

Pharmacogenetic Analysis in Mice

DESCRIPTION (provided by applicant): The goal of this research project is to demonstrate that genetic information can improve drug treatment regimens. The pharmacokinetic parameters for at least 4 different therapeutic agents will be measured across 11 inbred mouse strains. The strain-specific pharmacokinetic data will be evaluated using a haplotype-based computational method to identify the genetic loci responsible for the variation in pharmacokinetic responses. The computational predictions will be initially evaluated by correlation of allelic and gene expression patterns across inbred mouse strains, and with known information on the metabolism of these drugs. The effect that genetic alterations within the computationally predicted genes have on the metabolism of these drugs will be evaluated using in vitro and in vivo methodology. This experimental system will enable the factors effecting the metabolism of a drug to be efficiently and rapidly identified. Dosing regimens in mice based on information obtained from genotyping key loci will be developed and prospectively tested to evaluate the utility of genetically guided therapeutics. This model murine genetic system will assess the impact of genetically guided dose adjustment within a treatment population. If this approach is successfully applied to human therapy, it would have a significant impact on human health. To enable this, the following will be completed: 1) Polymorphisms in 150 murine genes effecting drug metabolism will be identified. 2) The pharmacokinetic profile (parent and metabolites) of coumadin, bleomycin, isoniazid and ritonavir will be measured in 11 inbred mouse strains. The genetic factors effecting this response will be computationally identified, and the effect that the predicted genes have on the metabolism of these drugs will be analyzed in vitro and in vivo. 3) One drug will be selected for evaluation of the utility of genetically guided dosing, and a clinical trial using genetically guided dosing will be performed in an experimental murine model.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R01
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    288917
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:288917\
  • Funding Mechanism
  • Study Section
    GNM
  • Study Section Name
    Genome Study Section
  • Organization Name
    ROCHE PALO ALTO, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    PALO ALTO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94304
  • Organization District
    UNITED STATES